Search research articles
Contact Us
Filters
Showing results (471-480 of 491) with videos related to
Page
of 50
Sort By:
The New England Journal of Medicine
|
October 5, 2022
Trial of Intravenous Immune Globulin in Dermatomyositis
Rohit Aggarwal, Christina Charles-Schoeman, Joachim Schessl, et al.
Journal of Neuromuscular Diseases
|
February 6, 2026
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study
Nicol C Voermans, Jeffrey M Statland, Lawrence J Hayward, et al.
The Lancet. Neurology
|
May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michael Benatar, Thomas Hansen, Dror Rom, et al.
The Lancet. Neurology
|
April 17, 2024
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
Rabi Tawil, Kathryn R Wagner, Johanna I Hamel, et al.
Indian Heart Journal
|
May 15, 2020
Cardiological society of India position statement on COVID-19 and heart failure
S Harikrishnan, P P Mohanan, V K Chopra, et al.
Muscle & Nerve
|
August 26, 2025
Multicenter Expanded Access Protocol for Research Through Access to Trehalose in People With Amyotrophic Lateral Sclerosis
Brooke Krivickas, Erica Scirocco, Elisa Giacomelli, et al.
Muscle & Nerve
|
January 8, 2017
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
Peter J Dyck, John C Kincaid, P James B Dyck, et al.
The Lancet. Neurology
|
August 10, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Michael G Hanna, Umesh A Badrising, Olivier Benveniste, et al.
JAMA Neurology
|
November 23, 2020
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial
Brian J Wainger, Eric A Macklin, Steve Vucic, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 24, 2020
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS
Jeremy M Shefner, Jinsy A Andrews, Angela Genge, et al.
Page
of 50
Search research articles
Search
Showing results (471-480 of 491) with videos related to
Sort By:
Page
of 50
The New England Journal of Medicine
|
October 5, 2022
Trial of Intravenous Immune Globulin in Dermatomyositis
Rohit Aggarwal, Christina Charles-Schoeman, Joachim Schessl, et al.
Journal of Neuromuscular Diseases
|
February 6, 2026
A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study
Nicol C Voermans, Jeffrey M Statland, Lawrence J Hayward, et al.
The Lancet. Neurology
|
May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michael Benatar, Thomas Hansen, Dror Rom, et al.
The Lancet. Neurology
|
April 17, 2024
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
Rabi Tawil, Kathryn R Wagner, Johanna I Hamel, et al.
Indian Heart Journal
|
May 15, 2020
Cardiological society of India position statement on COVID-19 and heart failure
S Harikrishnan, P P Mohanan, V K Chopra, et al.
Muscle & Nerve
|
August 26, 2025
Multicenter Expanded Access Protocol for Research Through Access to Trehalose in People With Amyotrophic Lateral Sclerosis
Brooke Krivickas, Erica Scirocco, Elisa Giacomelli, et al.
Muscle & Nerve
|
January 8, 2017
Assessing mNIS+7<sub>Ionis</sub> and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial
Peter J Dyck, John C Kincaid, P James B Dyck, et al.
The Lancet. Neurology
|
August 10, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Michael G Hanna, Umesh A Badrising, Olivier Benveniste, et al.
JAMA Neurology
|
November 23, 2020
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial
Brian J Wainger, Eric A Macklin, Steve Vucic, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 24, 2020
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS
Jeremy M Shefner, Jinsy A Andrews, Angela Genge, et al.
Page
of 50